Myeloproliferative Neoplasms News

The FDA granted fast track designation to momelotinib for the treatment of patients with intermediate- or high-risk myelofibrosis who previously received a JAK inhibitor.

CHICAGO — When treating patients with serious illnesses or at the end of life, the goal of clinicians should to be help draw out and then enact patients’ goals related to their well-being, satisfaction and affordability of treatment, Atul Gawande, MD, MPH, said during the opening ceremony of ASCO Annual Meeting.

Translating genomic and big data into clinical tools for physicians and patients with cancer is an enormous challenge that has been enthusiastically accepted by Aziz Nazha, MD, hematologist and medical oncologist at Cleveland Clinic Taussig Cancer Institute.

Individuals previously diagnosed with a hematologic malignancy appeared at higher risk for developing head and neck cancers, according to results of a retrospective study published in JAMA Otolaryngology – Head & Neck Surgery.

Survivors of allogeneic hematopoietic cell transplantation who underwent high-dose total body irradiation incurred nearly eight times the risk for subsequent malignant neoplasms compared with the general population, according to study results published in Blood.

Comprehensive molecular profiling feasibly identified potentially actionable mutations among children and adolescents with hard-to-treat cancers, according to results of a prospective study published in JAMA Network Open.

Patients with cancer who need a bone marrow transplant are less likely to find a suitable match if they are of southern-European or non-European descent, according to results of a prospective study published in Blood Advances.

Older adults with hematologic malignancies who require assistance with at least one basic or instrumental daily living activity have a higher risk for mortality than those who require no assistance, according to research published in Journal of the American Geriatrics Society.

The FDA granted fast track designation to APR-246 for the treatment of patients with myelodysplastic syndrome who have TP53 mutations.

Roy L. Silverstein, MD, began his 1-year term as ASH president in January.